Tenaya Therapeutics narrows third quarter 2026 net loss to $0.08 per share as FDA grants RMAT designation

Tenaya Therapeutics reported collaboration revenue of $1.7 million for the third quarter of 2026, compared to no revenue in the prior year period. The clinical-stage biotech narrowed its quarterly net loss and highlighted significant regulatory progress, including receiving the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its TN-401 gene therapy.

Key Highlights

• Net loss narrowed to $18.9 million ($0.08 per share) compared to $20.3 million ($0.12 per share) in the third quarter of 2025, driven by a slight decrease in R&D spending.
• Secured FDA RMAT designation for TN-401 for PKP2-associated ARVC, with additional interim data from the RIDGE-1 trial expected by year-end 2026.
• Cash and cash equivalents of $66.8 million provide a projected operational runway into the fourth quarter of 2027.